Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

BRIEF-Valeant updates on settlement agreements related to Salix unit

Published 2016-08-09, 06:00 p/m
© Reuters.  BRIEF-Valeant updates on settlement agreements related to Salix unit
BHC
-

Aug 9 (Reuters) - Valeant Pharmaceuticals (NYSE:VRX) VRX.TO

* Estimated legal liability, initially measured at fair value on date of Salix acquisition, should be reduced by $39 million

* Co and the states have executed settlement agreements concerning the states' portion of the settlement related to Salix

* Pursuant to terms of agreements, co will make a payment of about $8 million plus interest by august 18, 2016

* Following execution of settlement concerning federal claims against Salix, co concluded its estimated legal liability relating to this matter

* Adjustment was recorded in other income in Q2 of 2016 in the co's consolidated statement of loss Source text: Further company coverage: VRX.TO

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.